13F Holdings
中文EN

AUTL Autolus Therapeutics plc

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1730463 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY168.8%
TTM net income YoY-13.9%
TTM EPS YoY-15.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin35.8%
Operating margin-159.6%
Net margin-186.4%
FCF margin-131.1%
EBITDA margin-153.1%

Returns

ROE-174.9%
ROA-43.2%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets94.8%
Debt / equity0.00x
Current ratio3.72x
Interest coverage-4.79x

Cash quality & payout

Operating cash flow / net income0.69x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$75.39M$10.12M$1.70M——
Cost of revenue$96.37M$11.39M$0——
Gross profit-$20.98M-$1.27M$1.70M——
R&D expense$117.69M$138.44M$130.48M$117.35M$110.84M
SG&A expense$131.87M$101.72M$46.74M$31.90M$31.86M
Operating income-$270.54M-$241.43M-$179.70M-$143.41M-$141.05M
Interest expense$36.67M$9.29M$45.07M$8.90M$1.10M
Pretax income-$285.56M-$219.13M-$208.40M-$148.57M-$142.04M
Income tax$1.97M$1.53M-$19,000$272,000$58,000
Net income-$287.53M-$220.66M-$208.38M-$148.84M-$142.10M
EBITDA-$262.25M-$233.87M-$173.14M-$135.99M-$132.59M
EPS (basic)-1.08-0.86-1.20-1.57-1.97
EPS (diluted)-1.08-0.86-1.20-1.57-1.97
Weighted avg. shares (diluted)266.14M255.16M173.94M94.99M72.08M
Balance sheet
Cash & equivalents$104.13M$228.80M$240.34M$382.76M$310.34M
Short-term investments$196.58M$360.64M$0——
Receivables$24.02M$15,000$109,000$121,000$0
Inventory$33.21M$4.14M$0——
Current assets$435.92M$660.93M$275.30M$425.77M$346.95M
PP&E, net$63.56M$49.55M$34.86M$35.21M$33.54M
Intangibles$19.81M$12.37M$0$0$65,000
Total assets$589.07M$782.73M$375.38M$490.27M$405.56M
Current liabilities$73.44M$60.74M$44.74M$46.37M$28.55M
Total liabilities$410.94M$355.40M$263.91M$191.60M$92.24M
Shareholders' equity$178.13M$427.32M$111.47M$298.67M$313.32M
Cash flow statement
Operating cash flow-$283.57M-$206.27M-$145.59M-$112.31M-$117.86M
Capital expenditure$19.04M$22.07M$10.99M$10.84M$8.86M
Free cash flow-$302.61M-$228.35M-$156.57M-$123.15M-$126.72M
Investing cash flow$158.46M-$394.55M-$10.99M-$10.84M-$8.86M
Financing cash flow-$4.34M$589.55M-$883,000$223.61M$284.06M
Depreciation & amortization$8.30M$7.55M$6.57M$7.42M$8.46M
Stock-based compensation$14.44M$15.47M$11.20M$12.01M$9.94M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.